Low molecular weight heparin for the prevention of severe preeclampsia: where next?

No abstract is available for this paper.

• Publication year

  2018

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.13483PMID 29226532PMCID PMC5867115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low molecular weight heparin for the prevention of severe preeclampsia: where next?

  2018cited by this paper
• Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.

  2017cited by this paper
• THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand‐gated ion channels

  2017cited by this paper
• THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

  2017cited by this paper
• Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

  2017influential reference
• Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial

  2017cited by this paper
• Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.

  2016cited by this paper
• Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial

  2016cited by this paper
• Placental Pathology in Relation to Uterine Artery Doppler Findings in Pregnancies with Severe Intrauterine Growth Restriction and Abnormal Umbilical Artery Doppler Changes

  2016cited by this paper
• Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.

  2016cited by this paper
• Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.

  2016cited by this paper
• Abstract 12903: Low-molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High-risk of Preeclampsia

  2016cited by this paper
• Prevention of pre‐eclampsia by low‐molecular‐weight heparin in addition to aspirin: a meta‐analysis

  2016cited by this paper
• Persistent Maternal Cardiac Dysfunction After Preeclampsia Identifies Patients at Risk for Recurrent Preeclampsia

  2016cited by this paper
• Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor.

  2015cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  2015cited by this paper
• Faculty Opinions recommendation of Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy.

  2015cited by this paper
• Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort.

  2015cited by this paper
• Current Theories on the Prevention of Severe Preeclampsia With Low-Molecular Weight Heparin

  2015cited by this paper
• Global causes of maternal death: a WHO systematic analysis.

  2014cited by this paper
• IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia?

  2014cited by this paper
• Unfractionated heparin and placental pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial.

  2014cited by this paper
• Low-Molecular Weight Heparin Increases Circulating sFlt-1 Levels and Enhances Urinary Elimination

  2014cited by this paper
• IFPA Award in Placentology Lecture: preeclampsia, the decidual battleground and future maternal cardiovascular disease.

  2014cited by this paper
• Strategy for Standardization of Preeclampsia Research Study Design

  2014cited by this paper
• Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.

  2014cited by this paper
• Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications.

  2014cited by this paper
• Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia: A Prospective Multicenter Study

  2013cited by this paper
• Angiogenic factors combined with clinical risk factors to predict preterm pre‐eclampsia in nulliparous women: a predictive test accuracy study

  2013cited by this paper
• Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction.

  2013cited by this paper
• Redefining preeclampsia using placenta-derived biomarkers.

  2013cited by this paper
• Low‐molecular‐weight heparin added to aspirin in the prevention of recurrent early‐onset pre‐eclampsia in women with inheritable thrombophilia: the FRUIT‐RCT

  2012cited by this paper
• A Competing Risks Model in Early Screening for Preeclampsia

  2012cited by this paper
• Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia

  2012cited by this paper
• Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.

  2012cited by this paper
• Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery.

  2012cited by this paper
• Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort

  2011influential reference
• Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway

  2011cited by this paper
• Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia

  2011cited by this paper
• Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia

  2011cited by this paper
• Angiogenic Response of Placental Villi to Heparin

  2011cited by this paper
• Maternal cardiac function in preeclampsia

  2011cited by this paper
• Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae

  2010cited by this paper
• Vascular Dysfunction in Women With a History of Preeclampsia and Intrauterine Growth Restriction: Insights Into Future Vascular Risk

  2010cited by this paper
• Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension

  2010cited by this paper
• Angiogenic imbalances: the obstetric perspective.

  2010cited by this paper
• Dalteparin for the prevention of recurrence of placental‐mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial

  2009cited by this paper
• Early and Late Preeclampsia: Two Different Maternal Hemodynamic States in the Latent Phase of the Disease

  2008cited by this paper
• Predictive value of angiogenic factors and uterine artery Doppler for early‐ versus late‐onset pre‐eclampsia and intrauterine growth restriction

  2008cited by this paper
• Usefulness of a placental profile in high-risk pregnancies.

  2007cited by this paper
• Soluble endoglin contributes to the pathogenesis of preeclampsia

  2006cited by this paper
• Prophylaxis of Recurrent Preeclampsia: Low-Molecular-Weight Heparin plus Low-Dose Aspirin versus Low-Dose Aspirin Alone

  2006cited by this paper
• Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

  2006cited by this paper
• Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase

  2006cited by this paper
• Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone

  2006cited by this paper
• Comparison of the Vasodilatory Effect of Nadroparin, Enoxaparin, Dalteparin, and Unfractioned Heparin in Human Internal Mammary Artery

  2005cited by this paper
• Low-Molecular-Weight Heparin Lowers the Recurrence Rate of Preeclampsia and Restores the Physiological Vascular Changes in Angiotensin-Converting Enzyme DD Women

  2005cited by this paper
• Circulating Angiogenic Factors and the Risk of Preeclampsia

  2005cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• Fetal Growth and Body Proportion in Preeclampsia

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) could contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

  2003cited by this paper
• Hypertension in pregnancy

  1996cited by this paper
• Prevention of Preeclampsia with Heparin and Antiplatelet Drugs in Women with Renal Disease

  1995cited by this paper

• Kidney health outcomes of hypertensive disorders of pregnancy

  2025cites this paper
• Chronic hypertension in pregnancy: insights into adverse outcomes prevention

  2025cites this paper
• Secondary prevention of preeclampsia

  2025cites this paper
• LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling

  2024cites this paper
• Analogies between COVID-19 and Preeclampsia: Focus on Therapies

  2023cites this paper
• ПРОФІЛАКТИКА ПРЕЕКЛАМПСІЇ: СУЧАСНИЙ СТАН ПРОБЛЕМИ

  2023cites this paper
• Vascular Endothelial Cell Dysfunction in Preeclampsia

  2022cites this paper
• Prediction and Prevention of Preeclampsia

  2022cites this paper
• A bibliometric analysis of the research on preeclampsia in the first two decades of the twenty-first century

  2022cites this paper
• The role of thrombophilias in reproduction: A swot analysis.

  2022cites this paper
• Treating unexplained recurrent pregnancy loss based on lessons learned from obstetric antiphospholipid syndrome and inherited thrombophilia: A propensity-score adjusted retrospective study.

  2022cites this paper
• Perturbations in the kinetics of the thrombin generation assay identify women at risk for preeclampsia in the first trimester and provide a rationale for a preventive approach.

  2022cites this paper
• Alternative pathway activation in pregnancy, a measured amount “complements” a successful pregnancy, too much results in adverse events

  2022cites this paper
• Role of low molecular weight of heparin in preventing severe preeclampsia

  2022influential citation
• Genetic Mutations Pai-1 4G/4G and ACE D/D that Reduce Fibrinolysis are responsible for most Serious Pregnancy Complications and Abortions and are Best treated with S/C LMW Heparin and Aspirin

  2021cites this paper
• Stage stratification of pregnant women at risk of preeclampsia

  2021cites this paper
• FIGO (International Federation of Gynecology and Obstetrics) initiative on fetal growth: Best practice advice for screening, diagnosis, and management of fetal growth restriction

  2021cites this paper
• Low Molecular Weight Heparins (LMWH) and Implications along Pregnancy: a Focus on the Placenta

  2021cites this paper
• Circulating Maternal Placental Growth Factor Responses to Low Molecular Weight Heparin in Pregnant Patients at Risk of Placental Dysfunction.

  2021cites this paper
• Pre-eclampsia screening in the first trimester – preemptive action to prevent the peril

  2020cites this paper
• Low molecular weight heparin promotes transcription and release of placental growth factor from endothelial cells.

  2020cites this paper
• Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?

  2020cites this paper
• Does Race or Ethnicity Play a Role in the Origin, Pathophysiology, and Outcomes of Preeclampsia? An Expert Review of the Literature.

  2020cites this paper
• Preeclampsia. Eclampsia. Anesthesia and intensive care in childbirth and the puerperium. Review

  2020cites this paper
• Heparin Use in Pregnant Women Diagnosed With Thrombophilia: Obstetric Outcomes

  2019cites this paper
• Fetal Growth Restriction: Placental Basis and Implications for Clinical Practice

  2019cites this paper
• Low molecular weight heparin for the prevention of severe preeclampsia: where next?

  2018cites this paper
• Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia†

  2018cites this paper
• Infarction

  2018cites this paper
• Role of low molecular weight of heparin in preventing severe Role of low molecular weight of heparin in preventing severe preeclampsia

  year unknowncites this paper